FDA
-
-
-
-
-
-
-
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
-
-
-
-
-
-
-
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Oyster Point Pharma Inc. (OYST) Announces Coverage of TYRVAYA By the Largest Medicare Pharmacy Benefit Manager
-
-
-
-
-
-
-
Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022
-
-
-
-
-
-
-
Oyster Point Pharma Announces Operating Expense Streamlining Plan
-
-
-
-
-
-
-
Oyster Point Pharma To Report First Quarter 2022 Financial Results On May 5, 2022
-
-
-
-
-
-
-
Oyster Point Pharma Announces Retirement of William J. Link From Board of Directors
-
251,531 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All